An interventional study of Apelin and Acetylcholine in Heart Disease, Heart Failure and Vasodilatation, sponsored by University of Edinburgh. Completed at 1 site in United Kingdom. Open to participants aged 18 Months to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-08-10.
Sponsored by University of Edinburgh · Not applicable, Interventional, and Basic science
The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease.
Two of the main actions of apelin are to increase the pumping ability of the heart and cause blood vessels to relax. The investigators wish to assess if these actions are altered in the setting of normal renin-angiotensin activation and increased renin-angiotensin activity.
3,640 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.
This study's planned enrollment of 12 is below the median of 100 across 1,779 interventional studies indexed under Heart Diseases.
Browse Heart Diseases studies →University of Edinburgh is the lead sponsor of 393 studies on the registry; 64 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Subjects will be randomised to normal diet or sodium depleted diet. The sodium depletion protocol comprises of a single oral dose of 40 mg of furosemide followed by an out-patient diet containing \>2000 kcal of energy, \>60 g of protein, \<12 mmol of sodium and \<70 mmol of potassium per day for 3 days prior to study. This diet is know to increase the activity of the renin-angiotensin system.
Drug: Apelin · Drug: Acetylcholine · Drug: Sodium nitroprusside · Drug: Systemic apelin infusion
Subjects will be randomised to a normal diet, with no restriction on sodium intake during the three days prior to the study.
Drug: Apelin · Drug: Acetylcholine · Drug: Sodium nitroprusside · Drug: Systemic apelin infusion
Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.
Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min
Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min
Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals.
Change in cardiac output
Time frame: 12 months
Change in apelin mediated vasodilatation
Time frame: 12 months
Change in systemic haemodynamics
Time frame: 12 months
Change in relevant neurohumoral hormones
Time frame: 12 months
This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Edinburgh